| Dr Alfredo B Caragay, MD | |
|
1120 Saint Paul St, Ground Level, Baltimore, MD 21202-2618 | |
| (410) 685-7790 | |
| Not Available |
| Full Name | Dr Alfredo B Caragay |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine & Rehabilitation - Pain Medicine |
| Location | 1120 Saint Paul St, Baltimore, Maryland |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730404153 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2081P2900X | Physical Medicine & Rehabilitation - Pain Medicine | D0016332 (Maryland) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Alfredo B Caragay, MD 1120 Saint Paul St, Ground Level, Baltimore, MD 21202-2618 Ph: (410) 685-7790 | Dr Alfredo B Caragay, MD 1120 Saint Paul St, Ground Level, Baltimore, MD 21202-2618 Ph: (410) 685-7790 |
News Archive
Blue Cross Blue Shield of Michigan President and CEO Daniel J. Loepp made the following statement in conjunction with the news of legendary Detroit Tiger broadcaster Ernie Harwell's retirement to deal with a serious illness.
Researchers are exploring new approaches to designing prosthetic hands capable of providing "sensory feedback." Advances toward developing prostheses with a sense of touch are presented in a special topic article in the June issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.
Gilead Sciences, Inc. announced today that the European Commission has granted conditional marketing authorization for Cayston® 75 mg powder and solvent for nebuliser solution (aztreonam lysine) for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF) aged 18 years and older.
Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy.
Researchers from Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehensive Cancer Center, recently discovered a mechanism to explain what drives the formation of mucinous colorectal adenocarcinoma (MAC), a rare subtype of colorectal cancer (CRC), and has also identified the genes responsible for the regulation of this mechanism.
› Verified 8 days ago
Robert S Mayer, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 600 N Wolfe St, Baltimore, MD 21287 Phone: 410-532-4701 | |
Nia C Wallace Ward, PT, DPT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 707 N Broadway, Kennedy Krieger Institute, Baltimore, MD 21205 Phone: 443-923-9200 Fax: 443-923-9405 | |
Susan Miller, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 7500 Security Blvd, Mailstop: C1-09-06, Baltimore, MD 21244 Phone: 410-786-2118 | |
Christine Yunjae Wang, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2401 W Belvedere Ave, Baltimore, MD 21215 Phone: 410-601-9000 | |
Jason P Brokaw, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2700 Quarry Lake Drive, Suite 300, Baltimore, MD 21209 Phone: 410-377-8900 Fax: 410-377-3156 | |
Pablo Ariel Celnik, M.D. Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 600 N Wolfe St, Baltimore, MD 21287 Phone: 410-532-4701 | |
Behnam Jafarpour, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3421 Benson Ave, Suite 210, Baltimore, MD 21227 Phone: 443-693-7246 |